Year |
Citation |
Score |
2022 |
Gao X, Wang Y, Ribeiro CF, Manokaran C, Chang H, Von T, Rodrigues S, Cizmecioglu O, Jia S, Korpal M, Korn JM, Wang Z, Schmit F, Jiang L, Pagliarini R, et al. Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Molecular Cancer Research : McR. PMID 35105671 DOI: 10.1158/1541-7786.MCR-21-0322 |
0.323 |
|
2020 |
Ye LF, Reznik E, Korn JM, Lin F, Yang G, Malesky K, Gao H, Loo A, Pagliarini R, Mikkelsen T, Lo DC, deCarvalho AC, Stockwell BR. Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery. Oncotarget. 11: 443-451. PMID 32064048 DOI: 10.18632/Oncotarget.27457 |
0.386 |
|
2019 |
Li H, Ning S, Ghandi M, Kryukov GV, Gopal S, Deik A, Souza A, Pierce K, Keskula P, Hernandez D, Ann J, Shkoza D, Apfel V, Zou Y, Vazquez F, ... ... Pagliarini RA, et al. The landscape of cancer cell line metabolism. Nature Medicine. 25: 850-860. PMID 31068703 DOI: 10.1038/S41591-019-0404-8 |
0.374 |
|
2018 |
Liu H, Golji J, Brodeur LK, Chung FS, Chen JT, deBeaumont RS, Bullock CP, Jones MD, Kerr G, Li L, Rakiec DP, Schlabach MR, Sovath S, Growney JD, Pagliarini RA, et al. Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nature Medicine. PMID 30559422 DOI: 10.1038/S41591-018-0302-5 |
0.453 |
|
2018 |
Zhao Q, Manning JR, Sutton J, Costales A, Sendzik M, Shafer CM, Levell JR, Liu G, Caferro T, Cho YS, Palermo M, Chenail G, Dooley J, Villalba B, Farsidjani A, ... ... Pagliarini R, et al. Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors. Acs Medicinal Chemistry Letters. 9: 746-751. PMID 30034612 DOI: 10.1021/Acsmedchemlett.8B00182 |
0.402 |
|
2017 |
Cho YS, Levell JR, Liu G, Caferro T, Sutton J, Shafer CM, Costales A, Manning JR, Zhao Q, Sendzik M, Shultz M, Chenail G, Dooley J, Villalba B, Farsidjani A, ... ... Pagliarini R, et al. Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. Acs Medicinal Chemistry Letters. 8: 1116-1121. PMID 29057061 DOI: 10.1021/Acsmedchemlett.7B00342 |
0.405 |
|
2017 |
McDonald ER, de Weck A, Schlabach MR, Billy E, Mavrakis KJ, Hoffman GR, Belur D, Castelletti D, Frias E, Gampa K, Golji J, Kao I, Li L, Megel P, Perkins TA, ... ... Pagliarini RA, et al. Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell. 170: 577-592.e10. PMID 28753431 DOI: 10.1016/J.Cell.2017.07.005 |
0.434 |
|
2017 |
Levell JR, Caferro T, Chenail G, Dix I, Dooley J, Firestone B, Fortin PD, Giraldes J, Gould T, Growney JD, Jones MD, Kulathila R, Lin F, Liu G, Mueller A, ... ... Pagliarini R, et al. Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1. Acs Medicinal Chemistry Letters. 8: 151-156. PMID 28197303 DOI: 10.1021/Acsmedchemlett.6B00334 |
0.309 |
|
2017 |
Xie X, Baird D, Bowen K, Capka V, Chen J, Chenail G, Cho Y, Dooley J, Farsidjani A, Fortin P, Kohls D, Kulathila R, Lin F, McKay D, Rodrigues L, ... ... Pagliarini RA, et al. Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity. Structure (London, England : 1993). PMID 28132785 DOI: 10.1016/J.Str.2016.12.017 |
0.366 |
|
2016 |
Mounir Z, Korn JM, Westerling T, Lin F, Kirby CA, Schirle M, McAllister G, Hoffman G, Ramadan N, Hartung A, Feng Y, Kipp DR, Quinn C, Fodor M, Baird J, ... ... Pagliarini RA, et al. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor. Elife. 5. PMID 27183006 DOI: 10.7554/Elife.13964 |
0.346 |
|
2016 |
Mavrakis KJ, McDonald ER, Schlabach MR, Billy E, Hoffman GR, deWeck A, Ruddy DA, Venkatesan K, Yu J, McAllister G, Stump M, deBeaumont R, Ho S, Yue Y, Liu Y, ... ... Pagliarini R, et al. Disordered methionine metabolism in MTAP/CDKN2A deleted cancers leads to dependence on PRMT5. Science (New York, N.Y.). PMID 26912361 DOI: 10.1126/Science.Aad5944 |
0.477 |
|
2016 |
DiNardo CD, Schimmer AD, Yee KW, Hochhaus A, Kraemer A, Carvajal RD, Janku F, Bedard P, Carpio C, Wick A, Schwartz GK, Schöffski P, Wen P, van den Bent MJ, Rosenthal M, ... ... Pagliarini R, et al. A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations Blood. 128: 1073-1073. DOI: 10.1182/Blood.V128.22.1073.1073 |
0.303 |
|
2016 |
Mavrakis K, McDonald ER, Schlabach MR, Billy E, Hoffman GR, deWeck A, Ruddy DA, Venkatesan K, McAllister G, deBeaumont R, Ho S, Liu Y, Yan-Neale Y, Yang G, Lin F, ... ... Pagliarini R, et al. Abstract LB-017: Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to marked dependence on PRMT5 Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-017 |
0.406 |
|
2015 |
Pagliarini R, Shao W, Sellers WR. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. Embo Reports. 16: 280-96. PMID 25680965 DOI: 10.15252/Embr.201439949 |
0.391 |
|
2015 |
Mounir Z, Lin F, Lin VG, Korn JM, Yu Y, Valdez R, Aina OH, Buchwalter G, Jaffe AB, Korpal M, Zhu P, Brown M, Cardiff RD, Rocnik JL, Yang Y, ... Pagliarini R, et al. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene. 34: 3815-25. PMID 25263440 DOI: 10.1038/Onc.2014.308 |
0.386 |
|
2014 |
Chen Y, Chen J, Yu J, Yang G, Temple E, Harbinski F, Gao H, Wilson C, Pagliarini R, Zhou W. Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition. The Journal of Biological Chemistry. 289: 18914-27. PMID 24831003 DOI: 10.1074/Jbc.M114.574053 |
0.378 |
|
2014 |
Grassian AR, Parker SJ, Davidson SM, Divakaruni AS, Green CR, Zhang X, Slocum KL, Pu M, Lin F, Vickers C, Joud-Caldwell C, Chung F, Yin H, Handly ED, Straub C, ... ... Pagliarini R, et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Research. 74: 3317-31. PMID 24755473 DOI: 10.1158/0008-5472.Can-14-0772-T |
0.369 |
|
2014 |
Pop MS, Stransky N, Garvie CW, Theurillat JP, Hartman EC, Lewis TA, Zhong C, Culyba EK, Lin F, Daniels DS, Pagliarini R, Ronco L, Koehler AN, Garraway LA. A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein. Molecular Cancer Therapeutics. 13: 1492-502. PMID 24737027 DOI: 10.1158/1535-7163.Mct-13-0689 |
0.388 |
|
2014 |
Grassian AR, Pagliarini R, Chiang DY. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. Current Opinion in Gastroenterology. 30: 295-302. PMID 24569570 DOI: 10.1097/Mog.0000000000000050 |
0.336 |
|
2014 |
Grassian AR, Parker S, Davidson S, Divakaruni A, Green C, Zhang X, Slocum K, Pu M, Lin F, Vickers C, Joud-Caldwell C, Chung F, Yin H, Handly E, Straub C, ... ... Pagliarini R, et al. Abstract LB-139: IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-139 |
0.374 |
|
2014 |
Chen Y, Chen J, Loo A, Mclaughlin M, Pagliarini R, Zhou W. Abstract 682: Identification of HSP90 inhibitor sensitizers through pooled RNA interference screen Cancer Research. 74: 682-682. DOI: 10.1158/1538-7445.Am2014-682 |
0.408 |
|
2014 |
Pop M, Stransky N, Garvie C, Theurillat J, Lewis T, Zhong C, Culyba E, Lin F, Daniels D, Pagliarini R, Ronco L, Koehler A, Garraway L. Abstract 2519: A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein Cancer Research. 74: 2519-2519. DOI: 10.1158/1538-7445.Am2014-2519 |
0.384 |
|
2013 |
Chen J, Chung F, Yang G, Pu M, Gao H, Jiang W, Yin H, Capka V, Kasibhatla S, Laffitte B, Jaeger S, Pagliarini R, Chen Y, Zhou W. Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth. Oncotarget. 4: 2502-11. PMID 24318446 DOI: 10.18632/Oncotarget.1540 |
0.416 |
|
2013 |
Chen Y, Chen J, Loo A, Jaeger S, Bagdasarian L, Yu J, Chung F, Korn J, Ruddy D, Guo R, McLaughlin ME, Feng F, Zhu P, Stegmeier F, Pagliarini R, et al. Targeting HSF1 sensitizes cancer cells to HSP90 inhibition. Oncotarget. 4: 816-29. PMID 23615731 DOI: 10.18632/Oncotarget.991 |
0.383 |
|
2013 |
Lin F, Saenz-Vash V, Zhai H, Fletcher J, Acker M, Jiang D, Gounarides J, Levell J, Pagliarini R. Abstract A20: IDH mutations and 2-HG selectively affect histone methylation in the endogenous setting Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-A20 |
0.362 |
|
2013 |
Grassian AR, Parker S, Davidson S, Green C, Lin F, Joud-Caldwell C, Yin H, Chung F, Straub C, Heiden MV, Pagliarini R, Metallo C. Abstract B159: Heterozygous IDH1 mutations modify the citric acid (TCA) cycle metabolism and sensitize cells to inhibition of mitochondrial respiration/oxidative phosphorylation. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B159 |
0.412 |
|
2012 |
Grassian AR, Lin F, Barrett R, Liu Y, Jiang W, Korpal M, Astley H, Gitterman D, Henley T, Howes R, Levell J, Korn JM, Pagliarini R. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). The Journal of Biological Chemistry. 287: 42180-94. PMID 23038259 DOI: 10.1074/Jbc.M112.417832 |
0.407 |
|
2012 |
Pagliarini RA. Abstract IA20: A bad influence: ERG, AR, and prostate cell differentiation Cancer Research. 72. DOI: 10.1158/1538-7445.Prca2012-Ia20 |
0.362 |
|
2010 |
Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Research. 70: 6804-14. PMID 20699365 DOI: 10.1158/0008-5472.Can-10-0409 |
0.454 |
|
2009 |
Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (New York, N.Y.). 325: 1555-9. PMID 19661383 DOI: 10.1126/Science.1174229 |
0.305 |
|
2009 |
Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA, Kinzler KW, Vogelstein B, Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proceedings of the National Academy of Sciences of the United States of America. 106: 3964-9. PMID 19225112 DOI: 10.1073/Pnas.0813333106 |
0.307 |
|
2007 |
Srivastava A, Pastor-Pareja JC, Igaki T, Pagliarini R, Xu T. Basement membrane remodeling is essential for Drosophila disc eversion and tumor invasion. Proceedings of the National Academy of Sciences of the United States of America. 104: 2721-6. PMID 17301221 DOI: 10.1073/Pnas.0611666104 |
0.575 |
|
2006 |
Igaki T, Pagliarini RA, Xu T. Loss of cell polarity drives tumor growth and invasion through JNK activation in Drosophila. Current Biology : Cb. 16: 1139-46. PMID 16753569 DOI: 10.1016/J.Cub.2006.04.042 |
0.551 |
|
2003 |
Pagliarini RA, Xu T. A genetic screen in Drosophila for metastatic behavior. Science (New York, N.Y.). 302: 1227-31. PMID 14551319 DOI: 10.1126/science.1088474 |
0.501 |
|
2003 |
Pagliarini RA, Quiñones AT, Xu T. Analyzing the function of tumor suppressor genes using a Drosophila model. Methods in Molecular Biology (Clifton, N.J.). 223: 349-82. PMID 12777740 DOI: 10.1385/1-59259-329-1:349 |
0.505 |
|
Show low-probability matches. |